Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sercan Aksoy

Showing results (51-60 of 206) with videos related to

Pageof 21
Sort By:
Current Medical Research and Opinion|October 10, 2015
A comprehensive review of denosumab for bone metastasis in patients with solid tumorsGözde Gül, Mehmet A N Sendur, Sercan Aksoy, et al.
Cancers|June 10, 2022
The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-AnalysisDeniz Can Guven, Taha Koray Sahin, Enes Erul, et al.
The Prostate|March 15, 2023
Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with <sup>177</sup> Lu-PSMA-617. A single-center prospective observational studyTugce Telli, Murat Tuncel, Erdem Karabulut, et al.
Urologic Oncology|January 18, 2026
High AST and the presence of liver metastases may guide for the need for FDG PET in advanced prostate cancer patientsTugce Telli, Murat Tuncel, Erdem Karabulut, et al.
Expert Review of Anticancer Therapy|December 14, 2024
Post-operative serum CEA predicts prognosis in HR-positive/HER2-negative early breast cancerGozde Kavgaci, Taha Koray Sahin, Tugcenur Muderrisoglu, et al.
Cancer Nursing|March 29, 2019
The Reliability and Validity of the Turkish Version of the Lymphedema Life Impact Scale in Patients With Breast Cancer-Related LymphedemaCeren Orhan, Esra Üzelpasaci, Emine Baran, et al.
Molecular and Clinical Oncology|November 12, 2025
Prognostic significance of ductal carcinoma <i>in situ</i> coexisting with invasive ductal carcinoma: Biological behavior, immune response and survival outcomesNeslihan Koray Fedai, Ilgin Koc, Gozde Kavgaci, et al.
Critical Reviews in Oncology/Hematology|May 9, 2022
The efficacy of immune checkpoint inhibitors in rare tumors: A systematic review of published clinical trialsDeniz Can Guven, Bettzy Stephen, Taha Koray Sahin, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|February 18, 2014
Treatment and outcomes of Ewing sarcoma in Turkish adults: a single centre experienceMehmet Metin Seker, Tugba Kos, Nuriye Ozdemir, et al.
Pharmaceuticals (Basel, Switzerland)|July 27, 2024
Prognostic Significance of Pan-Immune-Inflammation Value in Patients with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab EmtansineTaha Koray Sahin, Arif Akyildiz, Osman Talha Dogan, et al.
Pageof 21

Showing results (51-60 of 206) with videos related to

Sort By:
Pageof 21
Current Medical Research and Opinion|October 10, 2015
A comprehensive review of denosumab for bone metastasis in patients with solid tumorsGözde Gül, Mehmet A N Sendur, Sercan Aksoy, et al.
Cancers|June 10, 2022
The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-AnalysisDeniz Can Guven, Taha Koray Sahin, Enes Erul, et al.
The Prostate|March 15, 2023
Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with <sup>177</sup> Lu-PSMA-617. A single-center prospective observational studyTugce Telli, Murat Tuncel, Erdem Karabulut, et al.
Urologic Oncology|January 18, 2026
High AST and the presence of liver metastases may guide for the need for FDG PET in advanced prostate cancer patientsTugce Telli, Murat Tuncel, Erdem Karabulut, et al.
Expert Review of Anticancer Therapy|December 14, 2024
Post-operative serum CEA predicts prognosis in HR-positive/HER2-negative early breast cancerGozde Kavgaci, Taha Koray Sahin, Tugcenur Muderrisoglu, et al.
Cancer Nursing|March 29, 2019
The Reliability and Validity of the Turkish Version of the Lymphedema Life Impact Scale in Patients With Breast Cancer-Related LymphedemaCeren Orhan, Esra Üzelpasaci, Emine Baran, et al.
Molecular and Clinical Oncology|November 12, 2025
Prognostic significance of ductal carcinoma <i>in situ</i> coexisting with invasive ductal carcinoma: Biological behavior, immune response and survival outcomesNeslihan Koray Fedai, Ilgin Koc, Gozde Kavgaci, et al.
Critical Reviews in Oncology/Hematology|May 9, 2022
The efficacy of immune checkpoint inhibitors in rare tumors: A systematic review of published clinical trialsDeniz Can Guven, Bettzy Stephen, Taha Koray Sahin, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|February 18, 2014
Treatment and outcomes of Ewing sarcoma in Turkish adults: a single centre experienceMehmet Metin Seker, Tugba Kos, Nuriye Ozdemir, et al.
Pharmaceuticals (Basel, Switzerland)|July 27, 2024
Prognostic Significance of Pan-Immune-Inflammation Value in Patients with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab EmtansineTaha Koray Sahin, Arif Akyildiz, Osman Talha Dogan, et al.
Pageof 21